Precision oncology decision support

Current approaches and strategies for the future

Katherine C. Kurnit, Ecaterina E. Ileana Dumbrava, Beate Litzenburger, Yekaterina B. Khotskaya, Amber M. Johnson, Timothy A. Yap, Jordi Rodon, Jia Zeng, Md Abu Shufean, Ann M. Bailey, Nora S. Sanchez, Vijaykumar Holla, John Mendelsohn, Kenna Mills Shaw, Elmer V. Bernstam, Gordon Mills, Funda Meric-Bernstam

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support.

Original languageEnglish (US)
Pages (from-to)2719-2731
Number of pages13
JournalClinical Cancer Research
Volume24
Issue number12
DOIs
StatePublished - Jun 15 2018
Externally publishedYes

Fingerprint

Neoplasms
Genomics
Health Personnel
Clinical Trials
Technology
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kurnit, K. C., Ileana Dumbrava, E. E., Litzenburger, B., Khotskaya, Y. B., Johnson, A. M., Yap, T. A., ... Meric-Bernstam, F. (2018). Precision oncology decision support: Current approaches and strategies for the future. Clinical Cancer Research, 24(12), 2719-2731. https://doi.org/10.1158/1078-0432.CCR-17-2494

Precision oncology decision support : Current approaches and strategies for the future. / Kurnit, Katherine C.; Ileana Dumbrava, Ecaterina E.; Litzenburger, Beate; Khotskaya, Yekaterina B.; Johnson, Amber M.; Yap, Timothy A.; Rodon, Jordi; Zeng, Jia; Shufean, Md Abu; Bailey, Ann M.; Sanchez, Nora S.; Holla, Vijaykumar; Mendelsohn, John; Shaw, Kenna Mills; Bernstam, Elmer V.; Mills, Gordon; Meric-Bernstam, Funda.

In: Clinical Cancer Research, Vol. 24, No. 12, 15.06.2018, p. 2719-2731.

Research output: Contribution to journalReview article

Kurnit, KC, Ileana Dumbrava, EE, Litzenburger, B, Khotskaya, YB, Johnson, AM, Yap, TA, Rodon, J, Zeng, J, Shufean, MA, Bailey, AM, Sanchez, NS, Holla, V, Mendelsohn, J, Shaw, KM, Bernstam, EV, Mills, G & Meric-Bernstam, F 2018, 'Precision oncology decision support: Current approaches and strategies for the future', Clinical Cancer Research, vol. 24, no. 12, pp. 2719-2731. https://doi.org/10.1158/1078-0432.CCR-17-2494
Kurnit KC, Ileana Dumbrava EE, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA et al. Precision oncology decision support: Current approaches and strategies for the future. Clinical Cancer Research. 2018 Jun 15;24(12):2719-2731. https://doi.org/10.1158/1078-0432.CCR-17-2494
Kurnit, Katherine C. ; Ileana Dumbrava, Ecaterina E. ; Litzenburger, Beate ; Khotskaya, Yekaterina B. ; Johnson, Amber M. ; Yap, Timothy A. ; Rodon, Jordi ; Zeng, Jia ; Shufean, Md Abu ; Bailey, Ann M. ; Sanchez, Nora S. ; Holla, Vijaykumar ; Mendelsohn, John ; Shaw, Kenna Mills ; Bernstam, Elmer V. ; Mills, Gordon ; Meric-Bernstam, Funda. / Precision oncology decision support : Current approaches and strategies for the future. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 12. pp. 2719-2731.
@article{bf8f3387fe1e4ee0b4626badcf1e38ac,
title = "Precision oncology decision support: Current approaches and strategies for the future",
abstract = "With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support.",
author = "Kurnit, {Katherine C.} and {Ileana Dumbrava}, {Ecaterina E.} and Beate Litzenburger and Khotskaya, {Yekaterina B.} and Johnson, {Amber M.} and Yap, {Timothy A.} and Jordi Rodon and Jia Zeng and Shufean, {Md Abu} and Bailey, {Ann M.} and Sanchez, {Nora S.} and Vijaykumar Holla and John Mendelsohn and Shaw, {Kenna Mills} and Bernstam, {Elmer V.} and Gordon Mills and Funda Meric-Bernstam",
year = "2018",
month = "6",
day = "15",
doi = "10.1158/1078-0432.CCR-17-2494",
language = "English (US)",
volume = "24",
pages = "2719--2731",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Precision oncology decision support

T2 - Current approaches and strategies for the future

AU - Kurnit, Katherine C.

AU - Ileana Dumbrava, Ecaterina E.

AU - Litzenburger, Beate

AU - Khotskaya, Yekaterina B.

AU - Johnson, Amber M.

AU - Yap, Timothy A.

AU - Rodon, Jordi

AU - Zeng, Jia

AU - Shufean, Md Abu

AU - Bailey, Ann M.

AU - Sanchez, Nora S.

AU - Holla, Vijaykumar

AU - Mendelsohn, John

AU - Shaw, Kenna Mills

AU - Bernstam, Elmer V.

AU - Mills, Gordon

AU - Meric-Bernstam, Funda

PY - 2018/6/15

Y1 - 2018/6/15

N2 - With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support.

AB - With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing number of trials are genomically selected. Furthermore, multiple studies have demonstrated the benefit of therapies that are chosen based upon the molecular profile of a tumor. However, the rapid evolution of genomic testing platforms and emergence of new technologies make interpreting molecular testing reports more challenging. More sophisticated precision oncology decision support services are essential. This review outlines existing tools available for health care providers and precision oncology teams and highlights strategies for optimizing decision support. Specific attention is given to the assays currently available for molecular testing, as well as considerations for interpreting alteration information. This article also discusses strategies for identifying and matching patients to clinical trials, current challenges, and proposals for future development of precision oncology decision support.

UR - http://www.scopus.com/inward/record.url?scp=85051820903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051820903&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-2494

DO - 10.1158/1078-0432.CCR-17-2494

M3 - Review article

VL - 24

SP - 2719

EP - 2731

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -